Phaseline

Targets › ABCB5

ABCB5 (ATP-binding cassette sub-family B member 5): drug programs, companies and trials

1 program from 1 company in 3 trials: 3 Phase 3; Cardiovascular, Other; next expected readout Jan 2027.

Energy-dependent efflux transporter responsible for decreased drug accumulation in multidrug-resistant cells. Specifically present in limbal stem cells, where it plays a key role in corneal development and repair (By similarity). (UniProt, Q2M3G0)

Open in Phaseline: the race on ABCB5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RHEACELL GmbH & Co. KGallo-APZ2-OTS
Allogeneic ABCB5-positive dermal mesenchymal stromal cells
ABCB5Phase 3Epidermolysis Bullosa; Venous Leg UlcerJan 2027

Conditions

Epidermolysis Bullosa (2) Venous Leg Ulcer (1)

Modalities

small molecule (1)

Companies

RHEACELL GmbH & Co. KG (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.